A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients with Platinum-resistant High-grade Ovarian Cancer (PROC) or R/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TUB 040 (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Ovarian cancer
Focus Adverse reactions; First in man
Acronyms NAPISTAR1-01
Sponsors Tubulis

Most Recent Events

20 Jun 2024 According to Tubulis media release, the first patient has been treated in its first Phase I/IIa trial following IND approval by the FDA.
23 May 2024 Status changed from not yet recruiting to recruiting.
15 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight